Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
about
The Role of Galectin-3 in the KidneysEthnic/Race Diversity and Diabetic Kidney DiseaseTrends in relative mortality between Hispanic and non-Hispanic whites initiating dialysis: a retrospective study of the US Renal Data System.Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar.African Americans, hypertension and the renin angiotensin systemClinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in type 2 diabetes mellitus patients.Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general populationObesity, metabolic syndrome and diabetic nephropathyDiabetic nephropathy among Mexican AmericansPerformance of a genetic risk score for CKD stage 3 in the general populationUrinary markers of glomerular injury in diabetic nephropathyObesity and diabetic kidney disease.Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy.CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC StudiesChronic kidney disease in United States Hispanics: a growing public health problem.Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.Hypertensive chronic kidney disease in African Americans: strategies for improving care.Does losartan prevent progression of early diabetic nephropathy in American Indians with type 2 diabetes?Elevated galectin-3 precedes the development of CKDThe antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo.CKD and cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study: interactions with age, sex, and race.Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney diseaseWhat should be the blood pressure target for patients with chronic kidney disease?Hypertension in black patients: an update.The effect of RAAS blockade on the progression of diabetic nephropathy.The role of novel biomarkers in predicting diabetic nephropathy: a review.CKD Progression and Mortality among Hispanics and Non-Hispanics.Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD.Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat.
P2860
Q26752754-B0000D25-5FAC-4ADE-9168-A01C0310422FQ26796594-FB68F9F2-BF63-46DA-B72C-6AF29D046A41Q30621295-C896172C-95B2-462D-9812-152BF9075541Q33721299-DF8B3733-E0F9-44AA-A7CF-AD9A3807C70EQ34251854-F023BB24-F8BD-4A49-B5AD-D5FD25F2A141Q34563525-C23282A1-C25B-42E6-8C6D-45D76C24281AQ35000389-45DAED52-4BE3-4C4D-BD42-4BF84EB00749Q35224446-B859EC3A-ADDD-4CDF-B229-21F79D05EA8EQ35530323-1BE2D1BA-B9E9-4496-A1DD-42AAFE5618E1Q35624242-8EDB5DD8-C44A-4F21-85D3-96E03CC81450Q35974945-60C9AB62-FBE3-4939-9FF7-A8C4C683343EQ36515043-B02D7275-3D87-44D6-9D0B-2B0848505934Q36589001-5CC4A1E1-F32A-48DD-94E6-48E9F3E284F7Q36623299-600216F5-A3C9-488F-AE7F-5F632BC69465Q36653353-4CE8BEF5-45C1-4276-891F-C754BDF96CE8Q36662162-308CF1CE-ED87-489B-84D1-58F360B9EB9CQ36666911-4AC932BC-DB77-467E-87B6-03CAA79BB889Q36713317-23A1C60B-5CF8-4534-B83F-6F0B740CB26FQ37110513-373B68B2-4C73-472E-9DD8-89AA367AAD24Q37119904-05372C4E-D094-4A3A-8227-3D12B496C1A1Q37142515-9E802634-8B52-4298-8052-DBAD27EC6A66Q37198527-249BF56F-E431-4CEE-841A-3DA248B3FA3FQ37219039-FD220F48-3C72-4250-91BA-05D540FCE672Q37263019-50CA4F1C-2B2C-44C4-9BFD-0FFB5401C7A1Q38113096-FA6EB5C7-9439-4D52-88F6-C63EFCED9937Q38168046-C9655A4B-9602-491F-B07E-A8BEE3EE7DFAQ38598929-D65FB586-FA8C-48B0-925A-A84A93BC7C86Q40502469-5887E6FB-76AB-484C-90F5-7F790537F8D0Q42703643-1C7D0594-BD66-4C0C-A20E-5E16006C288CQ45058875-52085392-0CD0-4DC5-A8D7-634553263AEAQ47874226-EC090B17-5BC6-4601-9CA4-D5EE9D981C4DQ47891550-22E27617-B23E-4D51-9490-44D490C1F1B9
P2860
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@en
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@nl
type
label
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@en
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@nl
prefLabel
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@en
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@nl
P2093
P356
P1433
P1476
Renal risk and renoprotection ...... a post hoc analysis of RENAAL.
@en
P2093
Brenner BM
Kurokawa K
Ribeiro AB
Shahinfar S
de Zeeuw D
P2888
P304
P356
10.1038/SJ.KI.5000326
P407
P577
2006-05-01T00:00:00Z